NASDAQ:XLO Xilio Therapeutics (XLO) Stock Price, News & Analysis $0.82 0.00 (0.00%) (As of 09/13/2024 08:54 PM ET) Add Compare Share Share Today's Range$0.79▼$0.8750-Day Range$0.74▼$1.0252-Week Range$0.49▼$2.89Volume273,600 shsAverage Volume593,907 shsMarket Capitalization$30.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Xilio Therapeutics alerts: Email Address Xilio Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.28Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.26) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector737th out of 927 stocksBiotechnology Industry11th out of 19 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Xilio Therapeutics.Read more about Xilio Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.13% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xilio Therapeutics has recently decreased by 72.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXilio Therapeutics does not currently pay a dividend.Dividend GrowthXilio Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XLO. Previous Next 2.9 News and Social Media Coverage News SentimentXilio Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Xilio Therapeutics this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Xilio Therapeutics is held by insiders.Percentage Held by Institutions54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xilio Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.26) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xilio Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xilio Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXilio Therapeutics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xilio Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Capital TrendsMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukraine was used to cyberattacks. But the WhisperGate attack just before Russia's full-scale invasion was different. It was larger... and it was aimed at dismantling Ukraine's critical infrastructure. The company's unique expertise and scalable approach allowed them to nearly double revenues between 2021-2023, and they've added another $20 million in new sales orders this year alone. There is no denying - the opportunity here is massive.Click here to learn how a small company is joining the ranks of Lockheed Martin and Raytheon About Xilio Therapeutics Stock (NASDAQ:XLO)Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.Read More XLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XLO Stock News HeadlinesSeptember 13 at 1:41 AM | americanbankingnews.comShort Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Drops By 72.1%August 28, 2024 | globenewswire.comXilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceSeptember 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk just built a supercomputer in Memphis, Tennessee. It took him only 122 days. Dubbed “Colossus,” this supercomputer aims to become the most powerful AI training system in the world. Housed in a 785,000 sq. ft facility in Memphis, Colossus will soon require 150 megawatts of electricity per day. That’s about equal to the amount of energy needed to power 100,000 homes per year. August 8, 2024 | investorplace.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024August 8, 2024 | finanznachrichten.deXilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsJune 13, 2024 | globenewswire.comXilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.May 14, 2024 | investorplace.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024September 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk just built a supercomputer in Memphis, Tennessee. It took him only 122 days. Dubbed “Colossus,” this supercomputer aims to become the most powerful AI training system in the world. Housed in a 785,000 sq. ft facility in Memphis, Colossus will soon require 150 megawatts of electricity per day. That’s about equal to the amount of energy needed to power 100,000 homes per year. May 14, 2024 | globenewswire.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsApril 17, 2024 | msn.comXilio Therapeutics (XLO) Price Target Increased by 17.86% to 5.61April 12, 2024 | stocknews.com3 Biotech Stocks to Invest In Right Now for Long-Term GainsApril 2, 2024 | investorplace.comXLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023April 1, 2024 | globenewswire.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsMarch 29, 2024 | marketwatch.comXilio Shares Take Flight Premarket After Gilead DealMarch 28, 2024 | investorplace.comWhy Is Xilio Therapeutics (XLO) Stock up 168% Today?March 28, 2024 | marketwatch.comXilio Therapeutics Plans Private Placement, Job CutsMarch 28, 2024 | markets.businessinsider.comXilio Prices Private Placement Of $11.3 Mln Of Shares, Updates XTX202 Trial; To Axe 21% Of JobsSee More Headlines Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/15/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:XLO CUSIPN/A CIK1840233 Webwww.xiliotx.com Phone857-524-2466FaxN/AEmployees73Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,400,000.00 Net MarginsN/A Pretax Margin-2,780.27% Return on Equity-173.95% Return on Assets-83.00% Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio2.02 Sales & Book Value Annual Sales$2.36 million Price / Sales12.84 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book0.61Miscellaneous Outstanding Shares36,912,000Free Float34,993,000Market Cap$30.27 million OptionableNot Optionable Beta-0.10 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Rene Russo BCPS (Age 49)Pharm.D., President, CEO & Director Comp: $875.13kMr. Christopher Frankenfield (Age 42)Chief Operating Officer Comp: $704.85kDr. Katarina Luptakova M.D. (Age 48)Chief Medical Officer Comp: $591.92kMr. Kevin M. Brennan (Age 54)Senior VP of Finance & Accounting Dr. Uli Bialucha Ph.D.Chief Scientific OfficerDr. Scott Coleman Ph.D.Chief Development OfficerMore ExecutivesKey CompetitorsImmunicNASDAQ:IMUXOptiNoseNASDAQ:OPTNEton PharmaceuticalsNASDAQ:ETONLifeVantageNASDAQ:LFVNRani TherapeuticsNASDAQ:RANIView All CompetitorsInsiders & InstitutionsXTX Topco LtdBought 33,289 shares on 8/12/2024Ownership: 0.076%Renaissance Technologies LLCBought 45,554 shares on 8/9/2024Ownership: 0.799%Gilead Sciences, Inc.Bought 485,250 shares on 4/2/2024Total: $368,790.00 ($0.76/share)Venture Fund Xi L.P. AtlasSold 733 sharesTotal: $469.12 ($0.64/share)Venture Fund Xi L.P. AtlasSold 1,566 sharesTotal: $1,362.42 ($0.87/share)View All Insider TransactionsView All Institutional Transactions XLO Stock Analysis - Frequently Asked Questions How have XLO shares performed this year? Xilio Therapeutics' stock was trading at $0.55 at the beginning of 2024. Since then, XLO shares have increased by 49.1% and is now trading at $0.82. View the best growth stocks for 2024 here. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.01. The firm had revenue of $2.36 million for the quarter, compared to analysts' expectations of $30 million. When did Xilio Therapeutics IPO? Xilio Therapeutics (XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share. Who are Xilio Therapeutics' major shareholders? Top institutional investors of Xilio Therapeutics include Renaissance Technologies LLC (0.80%) and XTX Topco Ltd (0.08%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Bain Capital Life Sciences Inv and Rock Springs Capital Managemen. View institutional ownership trends. How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XLO) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Turn Smartphones Into “Earnphones”?High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
